-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of…
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the…
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit…
Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage DeterminationCANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE)…
NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The global electronic health records…
WASHINGTON--(BUSINESS WIRE)--#CALiD--Perspectum, a leader in medical imaging quantification techniques, today announced that it has been awarded a 2024 U.S. Food…
Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025Company…
BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated…
SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed…
CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment…